Home > Riviste > Panminerva Medica > Fascicoli precedenti > Panminerva Medica 2018 June;60(2) > Panminerva Medica 2018 June;60(2):70-5

ULTIMO FASCICOLO
 

JOURNAL TOOLS

eTOC
Per abbonarsi PROMO
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Publication history
Estratti
Permessi
Per citare questo articolo

 

REVIEW   

Panminerva Medica 2018 June;60(2):70-5

DOI: 10.23736/S0031-0808.18.03394-3

Copyright © 2018 EDIZIONI MINERVA MEDICA

lingua: Inglese

A clinical update on metformin and lung cancer in diabetic patients

Gaurav GUPTA 1 , Terezinha de JESUS ANDREOLI PINTO 2, Dinesh K. CHELLAPPAN 3, Anurag MISHRA 4, Himaja MALIPEDDI 5, Kamal DUA 6, 7

1 School of Pharmaceutical Sciences, Jaipur National University, Jaipur, India; 2 Department of Pharmacy, Faculty of Pharmaceutical Sciences, University of São Paulo, São Paulo, Brazil; 3 School of Pharmacy, International Medical University, Bukit Jalil, Kuala Lumpur, Malaysia; 4 School of Pharmacy, Suresh Gyan Vihar University, Jagatpura, India; 5 Department of Chemistry, School of Advanced Sciences, VIT University, Vellore, India; 6 Discipline of Pharmacy, Graduate School of Health, University of Technology Sydney, Sydney, Australia; 7 School of Pharmaceutical Sciences, Shoolini University, Solan, India


PDF


Diabetes mellitus (DM) is frequently increased in many countries and become a serious health problem worldwide. Diabetes is associated with dysfunction of different organs such as heart, eyes, blood vessels, nerves, and kidneys. There is a strong connection between diabetes and cancer. Metformin is one of the most commonly prescribed oral antidiabetic medicines and it is suggested as the first-line therapy due to its comparatively safe, inexpensive, effective and well-tolerated. Some of the in vitro and in vivo investigations proved that metformin may have a direct anticancer action by preventing the proliferation of malignant cells and formations of the colony, inducing arrest of cell cycle and apoptosis and suppressing tumor growth. The antiproliferative mechanism of metformin alone or in combination with various chemotherapeutic agents is complex and involves several beneficial roles. In this regard, clinical studies are required to explain these roles. In the coming future, the use of metformin, alone or in combination with current chemotherapy, might be a conventional approach to effectually manage lung cancer. This mini-review provides a critical overview of currently available clinical trials investigating the effects of metformin in lung cancer.


KEY WORDS: Diabetes mellitus - Metformin - Lung neoplasms - AMP-activated protein kinases

inizio pagina